Physician

Hassan Kaleem, MD

According to 2025 Medicare claims, Hassan Kaleem, MD (NPI: 1538315676) practices radiation oncology in the Tulsa, OK market, with the plurality of this provider's patient population coming from Tulsa, OK. This provider's primary affiliated billing organization is OKLAHOMA CANCER AND BLOOD SPECIALISTS, LLC (NPI: 1831485267; TIN: 20-2001573) and primary practice location at 74137-4215.

Kaleem's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 271 traditional Medicare patients, billed 78,679 HCPCS/CPT codes, and received $1,917,161 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,574 prescription claims across 215 beneficiaries totaling $6,646,976 in drug costs, led by Octagam (Immun Globg(Igg)/Malt/Iga Ov50). 2021 DME data shows 34 claims. Open Payments data shows 337 records totaling $63,276. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $11,903 to $1,917,161. Similarly, Part D prescription costs have moved sharply higher in recent years, from $8,567 to $6,646,976. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	68	138	$11,903
2016	170	314	$25,222
2017	255	620	$50,895
2018	478	2,176	$198,734
2019	565	2,817	$258,086
2020	541	3,087	$269,702
2021	450	2,683	$247,823
2022	152	10,203	$207,654
2023	217	59,040	$1,245,851
2024	271	78,679	$1,917,161

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	61	159	$8,567
2016	62	158	$100,539
2017	123	359	$56,548
2018	167	1,414	$388,598
2019	212	1,681	$1,807,899
2020	208	1,731	$1,794,827
2021	187	1,297	$1,641,536
2022	103	364	$533,032
2023	151	1,134	$4,490,470
2024	215	1,574	$6,646,976

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	26	$4,024
2019	N/R	90	$6,117
2020	N/R	30	$860
2021	N/R	34	$3,451
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	79	79	$123
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	164	611	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	136	237	$63
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	89	140	$45
J1437	Injection, ferric derisomaltose, 10 mg	68	7,900	$16

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Octagam	Immun Globg(Igg)/Malt/Iga Ov50	124	3,171	$1,836,431
Procrit	Epoetin Alfa	227	6,356	$901,907
Xtandi	Enzalutamide	41	1,230	$564,833
Jakafi	Ruxolitinib Phosphate	23	690	$365,408
Darzalex Faspro	Daratumumab-Hyaluronidase-Fihj	12	336	$359,163

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	337	$63,276	Pharmacosmos Therapeutics Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Hassan Kaleem, MD?

Tedicare shows public-source Medicare data for Hassan Kaleem, MD (NPI 1538315676), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Hassan Kaleem, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Hassan Kaleem, MD?

Hassan Kaleem, MD is linked to OKLAHOMA CANCER AND BLOOD SPECIALISTS, LLC (billing NPI 1831485267) in the available physician profile data.

Does Hassan Kaleem, MD have Open Payments data?

Hassan Kaleem, MD has 337 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.